Related Experiment Video
Updated: May 6, 2026
Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging
Published on: December 15, 2014
The relative contrast ratio of malignant bone lesion is highest on relative Fat Fraction maps compared with
Francesca Castagnoli1, Alina Dragan1, Antonio Candito2
1Department of Radiology, Royal Marsden Hospital, Sutton, UK; Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, UK.
Introduction:
Whole-body MRI (WB-MRI) is increasingly used in clinical practice for detection of malignant bone disease. A high relative contrast ratio (RCR) of malignant bone lesions compared with normal bone can improve disease detection in breast, prostate and myeloma malignancies. However, the RCR of malignant bone lesions on T1w, DWI and relative Fat Fraction (rFF) maps derived from Dixon T1w have not been compared.
Methods:
110 baseline WB-MRI of patients with suspected malignant bone lesions were reviewed retrospectively. On each scan, up to four active bone lesions were identified, one each at the cervicothoracic spine, lumbosacral spine, pelvis and extremity, and their ROI signal intensity measured on rFF, T1w and DWI b = 900. The signal intensity of background bone was measured by placing an ROI on the nearest normal-appearing bone to each lesion, for each sequence. The mean lesion signal-to-background ratio (taken as RCR) for each lesion was calculated. We compared the RCR of bone lesions on rFF, T1w and DWI (Mann-Whitney test).
Results:
The median rFF RCR of malignant bone lesions was highest compared with normal bone marrow than that of T1w (p < 0.0001) and DWI (p < 0.0001). There was no significant difference in the median rFF RCR of malignant bone lesions from breast cancer, myeloma and prostate cancer (p > 0.017, Bonferroni correction) or according to their anatomical locations (p > 0.012, Bonferroni correction).
Conclusions:
Malignant bone lesion RCR measured by lesion/background signal intensity was higher on rFF than on T1w and DWI b = 900 in patients with prostate, breast and myeloma malignancies, indicating its value for disease detection.
